AstraZeneca Acknowledges Rare Thrombosis Risk in Covishield COVID-19 Vaccine
AstraZeneca has officially confirmed that its COVID-19 vaccine, Covishield, could lead to a rare condition known as Thrombosis with Thrombocytopenia Syndrome (TTS). Developed with the Serum Institute of India, Covishield's potential side effects have raised concerns across India.
Continue Reading